A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
Recruiting now · Phase 1
Conditions studied: Clear Cell Renal Cell Carcinoma, Solid Tumors
In brief
The purpose of this study is to evaluate the safety and tolerability of: * casdatifan when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and * casdatifan monotherapy and casdatifan in combination with cabozantinib or zimberelimab or zimberelimab and ipilimumab in participants with ccRCC in the dose expansion stage.
Key facts
- Study ID
- NCT05536141
- Run by
- Arcus Biosciences, Inc.
- People needed
- 362
- Starts
- 2022-10-26
- Expected to finish
- 2029-03-01
- Last updated by the study team
- 2026-07-29
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — Barcelona, Spain (enrolling)
- Research Site — San Diego, California, United States (enrolling)
- Research Site — Santa Monica, California, United States (enrolling)
- Research Site — Miami, Florida, United States (enrolling)
- Research Site — Atlanta, Georgia, United States (enrolling)
- Research Site — Louisville, Kentucky, United States (enrolling)
- Research Site — New Orleans, Louisiana, United States (enrolling)
- Research Site — Baltimore, Maryland, United States (enrolling)
- Research Site — Boston, Massachusetts, United States (enrolling)
- Research Site — Detroit, Michigan, United States (enrolling)
- Research Site — Detroit, Michigan, United States (enrolling)
- Research Site — Omaha, Nebraska, United States (enrolling)
- Research Site — New York, New York, United States (enrolling)
- Research Site — New York, New York, United States (enrolling)
- Research Site — Cleveland, Ohio, United States (enrolling)
- Research Site — Cleveland, Ohio, United States (enrolling)
- Research Site — Pittsburgh, Pennsylvania, United States (enrolling)
- Research Site — Nashville, Tennessee, United States (enrolling)
- Research Site — Nashville, Tennessee, United States (enrolling)
- Research Site — San Antonio, Texas, United States (enrolling)
- Research Site — Birmingham, Alabama, United States (enrolling)
- Research Site — Melbourne, Australia (enrolling)
- Research Site — Sydney, Australia (enrolling)
- Research Site — Seoul, South Korea (enrolling)
- Research Site — Camperdown, Australia
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.